ENGLEWOOD, Colo., Feb. 1, 2023
/PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative
medical technology company specializing in the manufacture and sale
of non-invasive medical devices for pain management, rehabilitation
and patient monitoring, today reported it will be hosting a blood
donation drive on February 1, 2023 at
its headquarters in Englewood, CO
in partnership with Vitalant, the nation's largest independent,
nonprofit blood services provider. The drive will fulfill an
important and immediate need to help with the emergency shortage of
blood in the community while also offering a unique research
opportunity for participants. Consenting donors will be monitored
with the Zynex Monitoring System, CM-1600 during the blood donation
as part of Zynex's IRB-approved Blood Loss Detection clinical
trial. The trial is designed to evaluate the specificity and
sensitivity of the CM-1600's patented Relative Index in detecting
blood loss. The company obtained FDA clearance of the previous
generation fluid monitoring system, the CM-1500, in February 2020. The CM-1600 is under review with
FDA.
"We value our research collaboration with Vitalant and are
excited at the opportunity for Zynex team members to give back to
the community by donating blood while also contributing to a
research study with our non-invasive monitoring technology," said
Donald Gregg, VP of Zynex Monitoring
Solutions.
Thomas Sandgaard, CEO, Chairman
and Founder said: "The need for blood donations across the country
is critical right now, and we are proud to be able to pioneer a
combined blood drive and research opportunity that advances science
and assists those that need it most. We look forward to hosting
more blood drives and research opportunities with Vitalant
throughout 2023."
About Zynex, Inc.
Zynex, founded in 1996, develops, manufactures, markets, and
sells medical devices used for pain management and rehabilitation
as well as non-invasive fluid, sepsis, and laser-based pulse
oximetry monitoring systems for use in hospitals. For additional
information, please visit: www.zynex.com.
Safe Harbor Statement
This release contains forward-looking statements within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore you should not rely on any of
these forward looking statements. The Company makes no express or
implied representation or warranty as to the completeness of
forward-looking statements or, in the case of projections, as to
their attainability or the accuracy and completeness of the
assumptions from which they are derived. Factors that could cause
actual results to materially differ from forward-looking statements
include, but are not limited to, the need to obtain CE marking of
new products, the acceptance of new products as well as existing
products by doctors and hospitals, larger competitors with greater
financial resources, the need to keep pace with technological
changes, our dependence on the reimbursement for our products from
health insurance companies, our dependence on third party
manufacturers to produce our products on time and to our
specifications, implementation of our sales strategy including a
strong direct sales force, the impact of COVID-19 on the global
economy and other risks described in our filings with the
Securities and Exchange Commission including but not limited to,
our Annual Report on Form 10-K for the year ended December 31, 2021 as well as our quarterly
reports on Form 10-Q and current reports on Form 8-K.
Any forward-looking statement made by us in this release is
based only on information currently available to us and speaks only
as of the date on which it is made. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Contact: Zynex, Inc. (800) 495-6670
Investor Relations Contact:
Gilmartin Group
Investor Relations Counsel
ir@zynex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/zynex-monitoring-announces-community-blood-drive-and-research-collaboration-trial-for-its-fluid-monitoring-system-301735819.html
SOURCE Zynex